Fair Value Measurements (Tables)

9 Months Ended

Mar. 31, 2017

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value

(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(5.2	)	$	(5.2	)
Interest rate derivative instruments	—		(1.3		)	—			(1.3		)
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(6.6	)	$	(5.2	)	$	(11.8	)

(in millions)	Level 1		Level 2		Level 3			Total
Contingent consideration	$	—	$	—	$	(15.9	)	$	(15.9	)
Interest rate derivative instruments	—		0.9		—			0.9
Foreign currency exchange contracts	—		0.8		—			0.8
Total	$	—	$	1.7	$	(15.9	)	$	(14.2	)

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:

Unobservable Input	Health Advances	ExecuPharm	TMAC
Risk free rate	1.3%	0.7%	1.5%
Revenue volatility	26%	29%	25%
Projected period of payment	Approximately 2 years	15 months	Approximately 3 years

The recurring Level 3 fair value measurements of our forward share repurchase contract asset include the following significant unobservable inputs:

	Forward Share
Unobservable Input	Repurchase Contract
Risk free rate	0.5%
Share price volatility	37.5%
Contract term	0.2 years

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table provides a summary of the change in our valuation of the fair value of the contingent consideration liability, which was determined by Level 3 inputs:

(in millions)
Balance at June 30, 2016	$	5.2
Additions of contingent consideration due to acquisitions	11.5
Change in fair value of contingent consideration	(0.8		)
Balance at March 31, 2017	$	15.9